On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2013: Volume 18/ Issue 21 Article 5
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 18, Issue 21, 23 May 2013
Rapid communications
A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013
  1. World Health Organization Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Victoria, Australia
  2. Monash University, School of Applied Sciences, Churchill, Victoria, Australia
  3. Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands

Citation style for this article: Baas C, Barr IG, Fouchier RA, Kelso A, Hurt AC. A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013. Euro Surveill. 2013;18(21):pii=20487. Available online:
Date of submission: 21 May 2013

Six antigen detection-based rapid influenza point-of-care tests were compared for their ability to detect avian influenza A(H7N9) virus. The sensitivity of at least four tests, standardised by viral infectivity (TCID50) or RNA copy number, was lower for the influenza A(H7N9) virus than for seasonal A(H3N2), A(H1N1)pdm09 or other recent avian A(H7) viruses. Comparing detection limits of A(H7N9) virus with Ct values of A(H7N9) clinical specimens suggests the tests would not have detected most clinical specimens.

Human infections with influenza viruses derived directly from wild birds or poultry are relatively rare, although since 2003, over 600 human infections with influenza A(H5N1) viruses have been detected, many of which were fatal [1]. During the same period, a small number of influenza A(H7) virus infections worldwide have also occurred in humans upon contact with infected poultry, generally resulting in mild symptoms such as conjunctivitis with occasional respiratory involvement and one death [2-4]. In contrast, China announced in March 2013 human infections with a novel reassortant avian influenza A(H7N9) virus which caused severe pneumonia resulting in a number of deaths [5]. Cases have occurred predominantly in men over 60 years of age living in urban areas, and most cases had a history of recent contact with poultry or poultry products [5]. By 16 May 2013, 131 human cases of influenza A(H7N9) virus infection, in 10 provinces and municipalities in eastern China, had been reported to the World Health Organization (WHO), of which 32 had resulted in death [6]. To date there have not been any reports of sustained human-to-human transmission of the influenza A(H7N9) virus, but the rapid emergence of the virus has led to significant concerns that it could in the future acquire human transmissibility and spread globally, causing the next influenza pandemic.

Rapid testing and diagnosis of possible human influenza A(H7N9) virus infections is an important diagnostic and public health task. An accurate diagnosis will allow the timely administration of antiviral therapy [7,8] and may also enable the quarantining of infected cases to prevent further spread of the virus. Real-time PCR is now considered the gold standard laboratory-based assay for the detection of influenza virus infections due to its high sensitivity and specificity [6] and, although such assays have already been developed for the detection of influenza A(H7N9) virus [6], they require a high level of laboratory expertise and may not be available in all places where cases occur.

Point-of-care tests (POCTs) based on antigen detection, however, are simple to use and are designed for use in a medical clinic or outpatient setting, enabling the rapid testing of patient specimens within 15 minutes [9]. POCTs have mostly been licensed for detection of seasonal human influenza viruses, for which they generally have good specificity but low sensitivity [10]. Recently however, some POCTs have been specifically developed to utilise automated readers which have resulted in improved sensitivity. For public health purposes, it is important to determine whether the new or existing POCTs can detect the novel influenza A(H7N9) virus, particularly as previous studies have found that some POCTs had poorer sensitivity in detecting avian influenza strains compared to circulating human seasonal influenza strains [9]. If POCTs could reliably detect influenza A(H7N9) virus at clinically relevant levels, they would be a useful adjunct to real-time PCR in the detection of possible human cases, especially where technical resources are limited.

We evaluated six widely available POCTs that are based on detection of the nucleoprotein antigen (Table 1) for their ability to detect the avian influenza A(H7N9) virus A/Anhui/01/2013 [5], compared with three other low pathogenic avian influenza A(H7) viruses (A/Northern Shoveller/Egypt-EMC/1/2012, A/Mallard/Netherlands/4/2010 and A/Mallard/Lithuania-EMC/2/2010), two human seasonal influenza A(H3N2) (A/Sydney/506/2013 and A/Victoria/361/2011) and two influenza A(H1N1)pdm09 viruses (A/Auckland/1/2009 and A/Brisbane/292/2010).

Table 1. Details of influenza point-of-care tests evaluated in this study


All viruses were cultured in Madin-Darby Canine Kidney (MDCK) cells at a low multiplicity of infection for at least one passage before testing. All viruses were harvested at near full cytopathic effect (CPE), supernatant was centrifuged at low speed to remove cell debris, and viruses were frozen at -70°C prior to testing. A mean tissue culture infectious dose 50 (TCID50) per mL was determined for each virus, based on at least three independent assays. Viruses were standardised to an infectivity titre of 1x106 TCID50/mL and then diluted in phosphate-buffered saline (PBS) in half-log10 dilutions. Real-time RT-PCR analysis was conducted on each virus dilution to determine a cycle threshold (Ct) value and RNA copy number, using an Applied Biosystems 7500 Fast cycler and the real-time RT-PCR primer and probe set recommended by the United States Centers for Disease Prevention and Control (US CDC) for the detection of influenza A matrix genes (version 4 April 2006). RNA copy number was calculated using a standard curve of RNA standards (10-fold dilutions) of known copy number prepared from a pGEMT-A/California/7/2009 matrix plasmid using the Riboprobe In Vitro Transcription System (Promega, United States).

Each virus dilution was then tested in each POCT according to the manufacturer’s instructions and a limit of detection (LOD), based on either the TCID50/mL or the RNA copy number/µL, was determined. Standardising viruses by viral infectivity (TCID50/mL) is the most widely used method for the evaluation of POCTs, however it does not account for defective viral particles which may react in these antigen-detection assays. Therefore comparison of the LOD based on both TCID50/mL and RNA copy number/µL (which accounts for both infective and defective viruses) can be informative. Half-log10 dilutions of influenza A/Anhui/01/2013 virus were prepared in duplicate and both sets tested with the six POCTs. The number of available test kits was not sufficient to conduct duplicate testing of the other seven viruses. The duplicate sets of influenza A/Anhui/01/2013 virus concentrations gave highly comparable LOD data, therefore data for only the first set is presented. Four of the kits were read by eye, while two POCTs (Veritor and Sofia) utilised a mechanical reader (Table 1).


Based on the TCID50/mL, the LOD of five of the six POCTs for the A/Anhui/01/2013 influenza A(H7N9) virus ranged from 1x105 to 1x105.5 TCID50/mL, with the Sofia and Directigen EZ detecting virus at the lower limit. The Clearview POCT was unable to detect the influenza A(H7N9) virus at any of the concentrations tested (1x106 TCID50/mL or lower) (Table 2). In comparison, the LOD of the POCTs for the other influenza A(H7) viruses tested was generally better than that seen with the A/Anhui/01/2013 virus, with some tests detecting virus levels as low as 1x102 TCID50/mL. Seasonal influenza A viruses were also more easily detected by most POCTs than the influenza A(H7N9) virus, with the Sofia kit performing best: LOD ranging from 1x102 to 1x103 TCID50/mL for the human influenza A(H3N2) and A(H1N1)pdm09 viruses.

Table 2. TCID50 limit of detection of the influenza point-of-care tests evaluated in this study


Comparison of POCT LODs based on RNA copy number/µL showed similar results to those based on TCID50/mL for four of the kits (Binax Now, Clearview, Veritor and Sofia). These POCTs were less sensitive for the  detection of  the influenza A(H7N9) virus compared to the seasonal or other influenza A(H7) viruses (Table 3). However, for the SD Bioline and the Directigen EZ tests, comparison of the LODs based on RNA copy number/µL showed that influenza A(H7N9) was detected at a similar sensitivity to the other viruses (Table 3).

Table 3. RNA copy number and Ct value limit of detection of the influenza point-of-care tests evaluated in this study

LODs based on RNA copy number/µL or Ct also allowed an estimate of the expected performance of the POCTs in detecting influenza A(H7N9) virus in clinical samples (Figure). Comparison of the published Ct values of clinical samples from patients with confirmed influenza A(H7N9) infection [11] suggested that five of the six POCTS would have detected only one of the four influenza A(H7N9)-positive clinical specimens, with the other three specimens being outside the LOD of these assays (Figure).

Figure. Mean Ct limit of detection for influenza A/Anhui/01/2013 in point-of-care tests compared with Ct values reported for four influenza A(H7N9) cases confirmed by RT-PCR


For all viruses tested, the Sofia POCT, which uses an automated reader, had the highest sensitivity. The BD Veritor test, which also uses an automated reader, had comparable sensitivity to the BD Directigen EZ and the Binax Now tests, both of which are read by eye. The Clearview and SD Bioline POCTs demonstrated the poorest sensitivity.

It is important to note that both the Clearview and the BD Veritor tests are only approved for analysis of swab specimens, therefore the test method used here may not have been appropriate. Similarly, all POCT assays may perform better using a particular specimen type, which was not tested here. The collection of the virus sample used for the Clearview and the BD Veritor POCTs (dipping the swab into liquid and waiting at least 15 seconds for absorption) resulted in a sample volume of approximately 50 μL which, when combined with the recommended diluent volume, resulted in the lowest concentrations of virus used in this evaluation (Table 1).

Other limitations of this study include the use of only a single influenza A(H7N9) isolate A/Anhui/01/2013 (although this virus is genetically closely related to other human influenza A(H7N9) viruses for which sequences have been reported) and the fact that clinical specimens were not available for analysis. It is also important to note that these POCTs have not been primarily designed or licensed to detect influenza A(H7N9) viruses or other avian-derived viruses.

Nevertheless, this study does demonstrate that the sensitivity of at least four of the six evaluated POCTs is lower for the novel influenza A(H7N9) virus than for seasonal influenza viruses and the other avian influenza A(H7) viruses tested. Comparison with published Ct values for clinical specimens from influenza A(H7N9) patients suggested that these POCTs may not detect the majority of influenza A(H7N9) cases, particularly if samples are taken late in the course of disease. Therefore RT-PCR remains the diagnostic test of choice for the testing of suspected influenza A(H7N9) influenza cases.

The authors are grateful to Dr Yuelong Shu and Dr  Dayan Wang, WHO Collaborating Centre for Reference and Research on Influenza, Chinese Center for Disease Control and Prevention, Beijing, China, for providing the A/Anhui/1/2013 A(H7N9) virus. We are grateful to Heidi Peck, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, for preparing the plasmid used for RNA quantitation. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing. RF was financed through NIAID-NIH contract HHSN266200700010C.

Conflict of interest
None declared

Authors’ contributions
Designed the study: CB, IB, AH. Analysed and interpreted the data: CB, RF, AK, IB and AH. Drafted the article: CB and AH. Revised the article: CB, RF, AK, IB and AH.


  1. World Health Organization (WHO). Influenza at the Human-Animal interface. Summary and assessment as of 26 April 2013.Geneva: WHO. [Accessed: 4 May 2013]. Available from:
  2. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101(5):1356-61.
    PMid:14745020 PMCid:337057
  3. Centers for Disease Control and Prevention (CDC). Notes from the field: Highly pathogenic avian influenza A (H7N3) virus infection in two poultry workers--Jalisco, Mexico, July 2012. MMWR Morb Mortal Wkly Rep. 2012;61(36):726-7.
  4. Belser JA, Bridges CB, Katz JM, Tumpey TM. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis. 2009;15(6):859-65.
    PMid:19523282 PMCid:2727350
  5. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. N Engl J Med. 2013;368(20):1888-97.
  6. World Health Organization (WHO). Number of confirmed human cases of avian influenza A(H7N9) reported to WHO. Geneva: WHO. [Accessed: 16 May 2013]. Available from:
  7. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363-73.
  8. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, et al. Early administration of oral oseltamivir increases the benifits of influenza treatment. J Antimicrob Chemother. 2003;51(1):123-9.
  9. Sakai-Tagawa Y, Ozawa M, Tamura D, Le M, Nidom CA, Sugaya N, et al. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol. 2010;48(8):2872-7.
    PMid:20554831 PMCid:2916590
  10. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol. 2007;39(2):132-5.
  11.  Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013; 25 April: pii: S0140-6736(13)60903-4.

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.